FATE Extends Runway to 2028 with 20% Q1 Operating Expense Reduction
Fate Therapeutics, Inc. · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $2.74
-19% in 3d after detection
Post-detection moves
1h
—
1d
-11%
3d
-19%
7d
+5.4%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS